Lung Cancer
Virtual Prehabilitation Is Efficacious Before Lung Cancer Surgery
January 30, 2021
Article
A virtual prehabilitaiton program improved patient outcomes before they underwent lung cancer surgery.
Mutations, irAEs May Help Predict Immunotherapy Response in NSCLC
January 29, 2021
Article
Patients with non-small cell lung cancer (NSCLC) who experience immune-related adverse events (irAEs) may have better survival outcomes than those without irAEs.
Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung Cancer
January 25, 2021
Article
The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.
Lung-Sparing Nodule Resection Needs Multidisciplinary Approach in Lung Cancer
January 25, 2021
Article
Although lung-sparing lung nodule resection in the form of lesser resection is available to some patients with lung cancer, it is critical to tailor surgical interventions based on pathologic assessment results, said Henning Gaissert, MD, who added that utilizing a multimodal approach to treatment can help alleviate some of the burden of treatment selection.
More Targets Discovered, More Molecular Testing Needed in Lung Cancer
January 09, 2021
Article
Molecular testing is a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET, according to Yujie Zhao, MD, PhD, who added that the integration of RNA-based sequencing into these strategies could potentially provide further benefit to patients.
Nivolumab's SCLC Approval Is Pulled From US Market
January 04, 2021
Article
Results of confirmatory trials showed that the drug did not meet its primary endpoints for patients with small cell lung cancer.
Expert Gives Lung Cancer Forecast for 2021
December 21, 2020
Article
Balazs Halmos, MD, discusses new advancements in lung cancer that are projected for 2021.
Adjuvant Osimertinib Approved for EGFR-Positive Lung Cancer
December 19, 2020
Article
The FDA has approved osimertinib (Tagrisso) for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Lung Cancer Advancements Continue, Despite COVID-19
December 03, 2020
Article
The coronavirus disease 2019 (COVID-19) pandemic has become another potential complication for patients with lung cancer, said Mark G. Kris, MD, who added that although the pandemic has disrupted patient care, it has yet to stunt scientific collaboration.
NP Explains Durvalumab' Benefit in NSCLC
November 14, 2020
Article
Durvalumab showed a promising survival boost in stage III non-small cell lung cancer, and the immunotherapy agent was not as toxic as some thought it would be.